Biopharmaceutics deal

The company's Anti-Sense Technologies Ltd. subsidiary agreed to purchase a 50 percent interest in an oligonucleotide compound from the Central Research Institute for Chemistry of the Hungarian Academy of Sciences. BPII said the compound has shown potential for inhibiting HIV reproduction in human cell culture. ...